| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TAK-715 | GDSC1000 | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.01 | 0.9 |
| mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | -0.0058 | 0.9 |
| mRNA | RAF265 | FIMM | pan-cancer | AAC | 0.033 | 0.9 |
| mRNA | KX2-391 | CTRPv2 | pan-cancer | AAC | -0.0059 | 0.9 |
| mRNA | BRD-K13999467 | CTRPv2 | pan-cancer | AAC | 0.0065 | 0.9 |
| mRNA | GDC-0941 | gCSI | pan-cancer | AAC | -0.01 | 0.9 |
| mRNA | BRD9876:MK-1775 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.02 | 0.9 |
| mRNA | AZD-7545 | CTRPv2 | pan-cancer | AAC | 0.0064 | 0.9 |
| mRNA | Axitinib | FIMM | pan-cancer | AAC | -0.029 | 0.9 |